Fusobacterium necrophorum: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 19: Line 19:
===Treatment===
===Treatment===
''F. necrophorum'' infection (also called F-throat<ref>{{cite web|url=http://www.peoplespharmacy.com/2015/02/19/sore-throat-misdiagnosis-could-kill-teenagers/|title=Sore Throat Misdiagnosis Could Kill Teenagers|publisher=[[WUNC (FM)|The People's Pharmacy]]|date=February 19, 2015|accessdate=February 20, 2015}}</ref>) usually responds to treatment with [[penicillin]] or [[metronidazole]], but penicillin treatment for persistent [[pharyngitis]] appears anecdotally to have a higher relapse rate, although the reasons are unclear.
''F. necrophorum'' infection (also called F-throat<ref>{{cite web|url=http://www.peoplespharmacy.com/2015/02/19/sore-throat-misdiagnosis-could-kill-teenagers/|title=Sore Throat Misdiagnosis Could Kill Teenagers|publisher=[[WUNC (FM)|The People's Pharmacy]]|date=February 19, 2015|accessdate=February 20, 2015}}</ref>) usually responds to treatment with [[penicillin]] or [[metronidazole]], but penicillin treatment for persistent [[pharyngitis]] appears anecdotally to have a higher relapse rate, although the reasons are unclear.
{{PBI|Fusobacterium necrophorum}}
:* Fusobacterium necrophorum treatment<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
::* 1. '''Hepatic abscess'''
:::* Preferred regimen (1): [[Metronidazole]] 500 mg PO q6h or [[Metronidazole]] 15 mg/kg IV q12h (max 4 gm/day) {{and}} ([[Ceftriaxone]] 1-2 gm IV q24h or [[Cefoxitin]] 2 gm IV q8h)
:::* Preferred regimen (2): [[Metronidazole]] 500 mg PO q6h or [[Metronidazole]] 15 mg/kg IV q12h (max 4 gm/day) {{and}} [[Ticarcillin-Clavulanate]] 3.1 gm IV q6h 
:::* Preferred regimen (3): [[Metronidazole]] 500 mg PO q6h or [[Metronidazole]] 15 mg/kg IV q12h (max 4 gm/day) {{and}} [[Piperacillin-Tazobactam]] 3.375 gm IV q4-6h
:::* Preferred regimen (4): [[Metronidazole]] 500 mg PO q6h or [[Metronidazole]] 15 mg/kg IV q12h (max 4 gm/day) {{and}} [[Amoxicillin]]-SB 3 gm IV q6h 
:::* Preferred regimen (5): [[Metronidazole]] 500 mg PO q6h or [[Metronidazole]] 15 mg/kg IV q12h (max 4 gm/day) {{and}} ([[Ciprofloxacin]] 400 mg IV q12h or [[Levofloxacin]] 750 mg IV q24h)
:::* Note: [[Ampicillin]] {{and}} [[Aminoglycoside]] {{and}} [[Metronidazole]] traditional & effective but [[Ampicillin]]-resistant gram negative bacilli increases and [[Aminoglycoside]] toxicity an issue.
:::* Alternative regimen (1): [[Metronidazole]] 500 mg PO q6h or [[Metronidazole]] 15 mg/kg IV q12h {{and}} [[Imipenem]] 0.5 gm IV q12h (max 4 gm/day),
:::* Alternative regimen (2): [[Metronidazole]] 500 mg PO q6h or [[Metronidazole]] 15 mg/kg IV q12h {{and}} [[Meropenem]] 1 gm IV q8h
:::* Alternative regimen (3): [[Metronidazole]] 500 mg PO q6h or [[Metronidazole]] 15 mg/kg IV q12h {{and}} [[Doripenem]] 500 mg IV q8h (1 hr infusion).
:::* Note: '''Serological tests for amebiasis should be done on all patients; if negative then surgical drainage or percutaneous aspiration.'''


===Infection in animals===
===Infection in animals===
Line 47: Line 26:


==Treatment==
==Treatment==
===Antimicrobial regimen===:* '''Fusobacterium necrophorum treatment'''<ref name="pmid22633566">{{cite journal| author=Kuppalli K, Livorsi D, Talati NJ, Osborn M| title=Lemierre's syndrome due to Fusobacterium necrophorum. | journal=Lancet Infect Dis | year= 2012 | volume= 12 | issue= 10 | pages= 808-15 | pmid=22633566 | doi=10.1016/S1473-3099(12)70089-0 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22633566  }} </ref>
===Antimicrobial regimen===
:* '''Fusobacterium necrophorum treatment'''<ref name="pmid22633566">{{cite journal| author=Kuppalli K, Livorsi D, Talati NJ, Osborn M| title=Lemierre's syndrome due to Fusobacterium necrophorum. | journal=Lancet Infect Dis | year= 2012 | volume= 12 | issue= 10 | pages= 808-15 | pmid=22633566 | doi=10.1016/S1473-3099(12)70089-0 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22633566  }} </ref>
::* 1. '''In adults'''
::* 1. '''In adults'''
:::* Preferred regimen: Combination therapy of [[Metronidazole]] 500 mg IV q8h {{and}} [[Ceftriaxone]] 2 gm IV q24h
:::* Preferred regimen: Combination therapy of [[Metronidazole]] 500 mg IV q8h {{and}} [[Ceftriaxone]] 2 gm IV q24h

Revision as of 14:35, 29 July 2015

WikiDoc Resources for Fusobacterium necrophorum

Articles

Most recent articles on Fusobacterium necrophorum

Most cited articles on Fusobacterium necrophorum

Review articles on Fusobacterium necrophorum

Articles on Fusobacterium necrophorum in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fusobacterium necrophorum

Images of Fusobacterium necrophorum

Photos of Fusobacterium necrophorum

Podcasts & MP3s on Fusobacterium necrophorum

Videos on Fusobacterium necrophorum

Evidence Based Medicine

Cochrane Collaboration on Fusobacterium necrophorum

Bandolier on Fusobacterium necrophorum

TRIP on Fusobacterium necrophorum

Clinical Trials

Ongoing Trials on Fusobacterium necrophorum at Clinical Trials.gov

Trial results on Fusobacterium necrophorum

Clinical Trials on Fusobacterium necrophorum at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fusobacterium necrophorum

NICE Guidance on Fusobacterium necrophorum

NHS PRODIGY Guidance

FDA on Fusobacterium necrophorum

CDC on Fusobacterium necrophorum

Books

Books on Fusobacterium necrophorum

News

Fusobacterium necrophorum in the news

Be alerted to news on Fusobacterium necrophorum

News trends on Fusobacterium necrophorum

Commentary

Blogs on Fusobacterium necrophorum

Definitions

Definitions of Fusobacterium necrophorum

Patient Resources / Community

Patient resources on Fusobacterium necrophorum

Discussion groups on Fusobacterium necrophorum

Patient Handouts on Fusobacterium necrophorum

Directions to Hospitals Treating Fusobacterium necrophorum

Risk calculators and risk factors for Fusobacterium necrophorum

Healthcare Provider Resources

Symptoms of Fusobacterium necrophorum

Causes & Risk Factors for Fusobacterium necrophorum

Diagnostic studies for Fusobacterium necrophorum

Treatment of Fusobacterium necrophorum

Continuing Medical Education (CME)

CME Programs on Fusobacterium necrophorum

International

Fusobacterium necrophorum en Espanol

Fusobacterium necrophorum en Francais

Business

Fusobacterium necrophorum in the Marketplace

Patents on Fusobacterium necrophorum

Experimental / Informatics

List of terms related to Fusobacterium necrophorum

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fusobacterium necrophorum is a species of bacteria responsible for Lemierre's syndrome and other medical problems.

Biology

F. necrophorum is a rod-shaped species of Gram-negative bacteria. It is an obligate anaerobe and is a common inhabitant of the alimentary tract within humans and animals.[1]

Pathogenicity

F. necrophorum is responsible for 10% of acute sore throats,[2] 21% of recurrent sore throats[3][4] and 23% of peritonsillar abscesses[5] with the remainder being caused by Group A streptococci or viruses. Other complications from F. necrophorum include meningitis, complicated by thrombosis of the internal jugular vein, thrombosis of the cerebral veins,[6] and infection of the urogenital and the gastrointestinal tracts.[7]

Although this infection is rare, researchers agree that this diagnosis should be considered in a septicaemic patient with thrombosis in an unusual site, and underlying malignancy should be excluded in cases of confirmed F. necrophorum occurring at sites caudal to the head.[8]

The above statistical analysis is dated, necessarily. A study in 2015 has f.necrophorum as the predominate causative organism in pharyngitis 21% of the time for a sample of university students at a single clinic in Alabama.[9]

Treatment

F. necrophorum infection (also called F-throat[10]) usually responds to treatment with penicillin or metronidazole, but penicillin treatment for persistent pharyngitis appears anecdotally to have a higher relapse rate, although the reasons are unclear.

Infection in animals

This bacterium has been found to be associated with the foot disease thrush in horses. Thrush is a common fungal infection that occurs on the hoof of a horse, specifically in the region of the frog. F. necrophorum occurs naturally in the animal's environment, especially in wet, muddy, or unsanitary conditions, such as an unclean stall.[11] [12] Horses with deep clefts, or narrow or contracted heels are more at-risk to develop thrush.

F. necrophorum is also a cause for lameness in sheep. Its infection is commonly called scald. It can last for several years on land used by either sheep or cattle, and is found on most land of this type throughout the world. Due to its survival length in these areas, it is unrealistic to try to remove it. Sheep most often get scald due to breakage or weakness of the skin surrounding the hoof. This can occur due to strong footbaths, sandy soils, mild frostbite, or prolongened waterlogging of a field, and results in denaturing of the skin between the cleats.[13]

Treatment

Antimicrobial regimen

  • Fusobacterium necrophorum treatment[14]
  • 1. In adults
  • 2. In children
  • Alternative regimen (1): Imipenem
  • Alternative regimen (2): Ampicillin-Sulbactam
  • Alternative regimen (3): antipseudomonal penicillins
  • Alternative regimen (4): Clindamycin
  • Note: More frequent dosing of ceftriaxone is needed in cases of CNS infection.


References

  1. Tan, Z. L.; Nagaraja, T. G.; Chengappa, M. M. "Fusobacterium necrophorum infections: Virulence factors, pathogenic mechanism and control measures". Veterinary Research Communications. 20 (2): 113–140. doi:10.1007/BF00385634.
  2. Aliyu SH, Marriott RK, Curran MD; et al. (2004). "Real-time PCR investigation into the importance of Fusobacterium necrophorum as a cause of acute pharyngitis in general practice". J Med Microbiol. 53 (Pt 10): 1029&ndash, 35. doi:10.1099/jmm.0.45648-0. PMID 15358827.
  3. Batty A, Wren MW. (2005). "Prevalence of Fusobacterium necrophorum and other upper respiratory tract pathogens isolated from throat swabs". Br J Biomed Sci. 62 (2): 66&ndash, 70. PMID 15997879.
  4. Batty A, Wren MW, Gal M. (2004). "Fusobacterium necrophorum as the cause of recurrent sore throat: comparison of isolates from persistent sore throat syndrome and Lemierre's disease". J Infect. 51 (4): 299&ndash, 306. doi:10.1016/j.jinf.2004.09.013. PMID 16051369.
  5. Klug TE, Rusan M, Fuursted K, Ovesen T (2009). "Fusobacterium necrophorum: most prevalent pathogen in peritonsillar abscess in Denmark". Clin Infect Dis. 49 (10): 1467&ndash, 1472. doi:10.1086/644616. PMID 19842975. line feed character in |author= at position 18 (help)
  6. Larsen PD, Chartrand SA, Adickes M. (1997). "Fusobacterium necrophorum meningitis associated with cerebral vessel thrombosis". Pediatr Infect Dis J. 16 (3): 330&ndash, 331. doi:10.1097/00006454-199703000-00017. PMID 9076827.
  7. Hagelskjaer Kristensen L, Prag J. (200). "Human necrobacillosis, with emphasis on Lemierre's syndrome". Clin Infect Dis. 31 (2): 524&ndash, 532. doi:10.1086/313970. PMID 10987717.
  8. Redford ML, Ellis R, Rees CJ. (2005). "Fusobacterium necrophorum infection associated with portal vein thrombosis". J Med Microbiol. 54 (5): 993&ndash, 995. doi:10.1099/jmm.0.46080-0. PMID 16157556.
  9. Robert M. Centor, MD; T. Prescott Atkinson, MD, PhD; Amy E. Ratliff, MLS; Li Xiao, PhD; Donna M. Crabb, MT (ASCP); Carlos A. Estrada, MD, MS; Michael B. Faircloth, MD; Lisa Oestreich, DO; Jeremy Hatchett, MD; Walid Khalife, PhD; and Ken B. Waites, MD (2015). "The Clinical Presentation of Fusobacterium-Positive and Streptococcal-Positive Pharyngitis in a University Health Clinic: A Cross-sectional Study". Ann Intern Med. 162 (4): 241&ndash, 247. doi:10.7326/M14-1305.
  10. "Sore Throat Misdiagnosis Could Kill Teenagers". The People's Pharmacy. February 19, 2015. Retrieved February 20, 2015.
  11. https://www.thehorse.com/articles/27319/the-lowdown-on-thrush
  12. Ensminger, M. E. (1990). Horses and Horsemanship: Animal Agriculture Series (Sixth ed.). Danville, IL: Interstate Publishers. p. 62. ISBN 0-8134-2883-1.
  13. http://www.defra.gov.uk/animalh/welfare/pdf/sheeplameness.pdf
  14. Kuppalli K, Livorsi D, Talati NJ, Osborn M (2012). "Lemierre's syndrome due to Fusobacterium necrophorum". Lancet Infect Dis. 12 (10): 808–15. doi:10.1016/S1473-3099(12)70089-0. PMID 22633566.

Further reading

[1]

  1. Machado, Vinícius Silva (March 17, 2014). "Subcutaneous Immunization with Inactivated Bacterial Components and Purified Protein of Escherichia coli, Fusobacterium necrophorum and Trueperella pyogenes Prevents Puerperal Metritis in Holstein Dairy Cows". PLoS ONE (2014). 9 (3): e91734. doi:10.1371/journal.pone.0091734.